FDA Panel Supports MS Drug's Market Return (AP via Yahoo! News)
A promising drug for multiple sclerosis should be returned to the market despite questions about a rare brain disease, scientific advisers told the government Wednesday even as they continued to grapple with just who should be allowed to use it.